Asciminib after stem cell transplant for Ph+ B-ALL or blast-phase CML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding the drug asciminib to standard care after a stem cell transplant can help keep certain types of leukemia from coming back. Asciminib is a type of targeted therapy that blocks a specific protein driving the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have Ph+ B-ALL (a type of acute lymphoblastic leukemia) or blast-phase CML (chronic myeloid leukemia that has progressed).
- You have already had a stem cell transplant (allogeneic HSCT).
- You received a tyrosine kinase inhibitor (TKI) therapy (like imatinib, dasatinib, etc.) as part of your previous treatment.
- Your blood counts meet minimum levels (absolute neutrophil count >= 1.0 x 10^9/L and platelets >= 50 x 10^9/L).
- You are willing to take a standard TKI for maintenance after transplant (asciminib is added on top).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted pill (olverembatinib) given after a stem cell transplant to help prevent leukemia from coming back in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It may also be used early if signs of the disease appear.
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
Hear when a new Ph+ Acute Lymphoblastic Leukemia (Ph+ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.